Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter

Diabetologia

Volumn 51, Issue 1, 2008, Pages 175-182

  Meyer, J A ^a   Froelich, J M ^b   Reid, G E ^b,c   Karunarathne, W K A ^a   Spence, D M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Michigan State University   (United States)

Author keywords

C peptide; Chromium; Diabetes; Erythrocytes; Glucose transport; GLUT1

Indexed keywords

ADENOSINE TRIPHOSPHATE; C PEPTIDE; CARBON 14; CHROMIUM; GLUCOSE; GLUCOSE TRANSPORTER 1; IRON; MANNOSE; METAL COMPLEX; NITRIC OXIDE; NUCLEOTIDE; PHLORETIN;

ANIMAL CELL; ARTICLE; CHEMOLUMINESCENCE; CLEARANCE; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME RELEASE; ERYTHROCYTE; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; INCUBATION TIME; MALE; METAL BINDING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RABBIT; STIMULATION; STIMULUS;

ADENOSINE TRIPHOSPHATE; ANIMALS; C-PEPTIDE; CHROMIUM; ERYTHROCYTES; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HUMANS; IRON; MALE; METALS; MODELS, BIOLOGICAL; NITRIC OXIDE; RABBITS;

EID: 36649008678     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-007-0853-3     Document Type: Article

References (25)

1. Kunt T, Forst T, Pfutzner A, Beyer J, Wahren J (1999) The physiological impact of proinsulin C-peptide. Pathophysiology 5:257-262
2. Johansson BL, Kernell A, Sjoberg S, Wahren J (1993) Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab 77:976-981
3. Johansson BL, Sjoeberg S, Wahren J (1992) The influence of human C-peptide on renal function and glucose utilisation in type 1 (insulin-dependent) diabetic patients. Diabetologia 35:121-128
4. Ido Y, Vindigni A, Chang K et al (1997) Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 277:563-566
5. Forst T, Kunt T (2004) Effects of C-peptide on microvascular blood flow and blood hemorheology. Exp Diabesity Res 5:51-64
6. Forst T, Kunt T, Pohlmann T et al (1998) Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest 101:2036-2041
7. Kunt T, Schneider S, Pfutzner A et al (1999) The effect of human proinsulin C-peptide on erythrocyte deformability in patients with type I diabetes mellitus. Diabetologia 42:465-471
8. Wallerath T, Kunt T, Forst T et al (2003) Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide 9:95-102
9. Sprague RS, Stephenson, Alan H et al (1995) Effect of l-NAME on pressure-flow relationships in isolated rabbit lungs: role of red blood cells. Am J Physiol Heart Circ Physiol 269:H1941-H1948
10. Sprague RS, Ellsworth, Mary L et al (1996) ATP: the red blood cell link to NO and local control of the pulmonary circulation. Am J Physiol Heart Circ Physiol 271:H2717-H2722
11. Sprague RS, Ellsworth ML, Stephenson AH, Kleinhenz ME, Lonigro AJ (1998) Deformation-induced ATP release from red blood cells requires cystic fibrosis transmembrane conductance regulator activity. Am J Physiol 275:H1726-H1732
12. Sprague RS, Olearczyk JJ, Spence DM, Stephenson AH, Sprung RW, Lonigro AJ (2003) Extracellular ATP signaling in the rabbit lung: erythrocytes as determinants of vascular resistance. Am J Physiol 285:H693-H700
13. i in erythrocytes of humans with type 2 diabetes is associated with impairment of both cAMP generation and ATP release. Diabetes 55:3588-3593
14. Carroll JS, Subasinghe W, Raththagala M et al (2006) An altered erythrocyte pentose phosphate pathway affects the ability of red cells to release ATP, a nitric oxide stimulus. Mol Biosys 2:305-311
15. Sprung RJ, Sprague RS, Spence DM (2002) Determination of ATP release from erythrocytes using microbore tubing as a model of resistance vessels in vivo. Anal Chem 74:2274-2278
16. Simpson LO (1985) Intrinsic stiffening of red blood cells as the fundamental cause of diabetic nephropathy and microangiopathy: a new hypothesis. Nephron 39:344-351
17. Schwartz RS, Madsen JW, Rybicki AC, Nagel RL (1991) Oxidation of spectrin and deformability defects in diabetic erythrocytes. Diabetes 40:701-712
18. Wahren J, Ekberg K, Jornvall H (2007) C-peptide is a bioactive peptide. Diabetologia 50:503-509
19. Wahren J, Ekberg K, Samnegard B, Johansson BL (2001) C-peptide: a new potential in the treatment of diabetic nephropathy. Curr Diab Rep 1:261-266
20. Stevens M, Zhang W, Li F, Sima A (2004) C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 287:E497-E505
21. Johansson BL, Linde B, Wahren J (1992) Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type I (insulin-dependent) diabetic patients. Diabetologia 35:1151-1158
22. Luzi L, Zerbini G, Caumo A (2007) C-peptide: a redundant relative of insulin? Diabetologia 50:500-502
23. Henriksson M, Shafqat J, Liepinsh E et al (2000) Unordered structure of proinsulin C-peptide in aqueous solution and in the presence of lipid vesicles. Cell Mol Life Sci 57:337-342
24. Henriksson M, Nordling E, Melles E et al (2005) Separate functional features of proinsulin C-peptide. Cell Mol Life Sci 62:1772-1778
25. Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881-885